Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLANTIC: Intravitreal aflibercept monotherapy vs aflibercept with adjunctive photodynamic therapy in polypoidal choroidal vasculopathy
2015-001368-20Phase 4Completed
- Sponsor
- AIBILI
- Start
- Jul 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aflibercept in polypoidal choroidal vasculopathy (PCV) and age-related macular degeneration (AMD) (2 arms), sponsored by AIBILI. Primary endpoint: Change in BCVA from baseline to week 52. Started Jul 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
polypoidal choroidal vasculopathy (PCV)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2015-001368-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001368-20.